Information  X 
Enter a valid email address

Diurnal Group PLC Ord GBP0.05 (DNL)

Date Time Source Announcement
15 Oct 2021 11:17 am
RNS
Holding(s) in Company
14 Oct 2021 7:01 am
RNS
Appointment of Joint Corporate Broker
  7:00 am
RNS
Agreement signed with ExCEEd Orphan for CEE
11 Oct 2021 7:00 am
RNS
Phase 1 data for DITEST published in EJE
08 Oct 2021 12:24 pm
RNS
Exercise of Options, Issue of Equity and TVR
07 Oct 2021 11:15 am
EQS
Hardman & Co Research | Diurnal (DNL) Life Sciences Investor Forum
06 Oct 2021 3:53 pm
RNS
Posting of Annual Report and Notice of AGM
30 Sep 2021 12:08 pm
RNS
Holding(s) in Company
29 Sep 2021 2:35 pm
RNS
Holding(s) in Company
17 Sep 2021 7:00 am
RNS
Hardman & Co Life Sciences Investor Forum
16 Sep 2021 10:15 am
EQS
Diurnal Group (DNL): All set for three pivotal trials
15 Sep 2021 9:17 am
RNS
Director Dealings
14 Sep 2021 7:00 am
RNS
Results for the year ended 30 June 2021
13 Sep 2021 7:00 am
RNS
Commercial launch of Efmody in the UK
01 Sep 2021 7:00 am
RNS
Diurnal launches Efmody in Germany and Austria
19 Aug 2021 7:00 am
RNS
Full Year Results Investor Presentation
12 Aug 2021 7:20 am
EQS
Hardman & Co Video Event | Diurnal Group plc - Investor Forum
02 Aug 2021 7:00 am
RNS
Grant of Deferred Share Awards
28 Jul 2021 7:00 am
RNS
Business and Trading Update
14 Jul 2021 7:00 am
RNS
Director Dealings
12 Jul 2021 7:00 am
RNS
Agreement from US FDA on SPA for Chronocort
09 Jul 2021 8:30 am
RNS
Director Dealings and Issue of Equity
07 Jul 2021 7:00 am
RNS
Notice of Full Year Results
05 Jul 2021 7:00 am
RNS
Shares and AJ Bell Investor Evening Webinar
02 Jul 2021 7:00 am
RNS
Marketing Authorisation for Efmody in GB from MHRA
29 Jun 2021 7:00 am
RNS
Distribution agreement with Er-Kim
02 Jun 2021 12:19 pm
RNS
Director Dealings
01 Jun 2021 7:00 am
RNS
Diurnal triggers milestone payments from Citrine
28 May 2021 2:33 pm
RNS
European Commission approval received for Efmody
13 May 2021 7:00 am
RNS
Correction: Director Dealings
12 May 2021 5:32 pm
RNS
Director Dealings
  3:44 pm
RNS
Director Dealings
  1:58 pm
RNS
Holding(s) in Company
  12:08 pm
RNS
Holding(s) in Company
  7:00 am
RNS
Agreement with Citrine Medicine for Efmody
11 May 2021 4:43 pm
RNS
Holding(s) in Company
  3:25 pm
RNS
Holding(s) in Company
10 May 2021 10:26 am
RNS
Result of General Meeting
23 Apr 2021 7:00 am
RNS
Grant of second European Patent for Alkindi
21 Apr 2021 11:51 am
RNS
Result of Placing and Subscription
  7:00 am
RNS
Proposed Placing, Subscription and Open Offer
15 Apr 2021 9:49 am
RNS
Request for Efmody Orphan Designation withdrawn
26 Mar 2021 2:06 pm
RNS
Second Price Monitoring Extn
  2:00 pm
RNS
Price Monitoring Extension
  11:57 am
RNS
EMA issues positive opinion for second product
15 Mar 2021 7:00 am
EQS
Diurnal Group (DNL): Initiation - Improving treatments for endocrine disorders
10 Mar 2021 9:44 am
RNS
Holding(s) in Company
08 Mar 2021 5:34 pm
RNS
Holding(s) in Company
25 Feb 2021 7:15 am
EQS
Diurnal Group (DNL): Attention turning to Chronocort(R)
24 Feb 2021 7:00 am
RNS
Shares and AJ Bell Investor Evening Webinar
23 Feb 2021 7:01 am
RNS
Interim Results
  7:00 am
RNS
Chronocort agreement with Consilient for Nordics
02 Feb 2021 7:01 am
RNS
Chronocort results published in JCEM
27 Jan 2021 9:00 am
RNS
Price Monitoring Extension
  7:00 am
RNS
China licencing agreement with Citrine for Alkindi
14 Jan 2021 7:01 am
RNS
Business and trading update
  7:00 am
RNS
Agreement with Eton for Alkindi extended to Canada
13 Jan 2021 10:07 am
RNS
Agreement with Er-Kim for distribution in Turkey
12 Jan 2021 7:00 am
RNS
Chronocort MAA Submitted to the UK MHRA

a d v e r t i s e m e n t